Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? - The Globe and Mail

Drug approval Patent expiry AI-generated analysis

πŸ“‰ Bristol Myers Squibb trades at just 9.4x forward earnings versus an 18.5x sector average, signaling potential undervaluation.

πŸ’° The company reported a 6% year-over-year revenue increase to $13 billion in the second quarter with non-GAAP EPS rising 40% to $2.04.

🧬 Key assets Eliquis and Opdivo contributed over half of total revenue, though both face patent exclusivity losses by the end of the decade.

πŸ’‰ The launch of Opdivo Qvantig aims to retain patients from the original formulation as it loses patent protection through easier administration.

πŸ”¬ Bristol Myers is developing pumitamig in partnership with BioNTech and milvexian as potential successors to its expiring blockbuster drugs.

πŸ’΅ The stock offers a 4% forward dividend yield, significantly higher than the S&P 500 average of 1.1%, with payouts increased by 65.8% over the last decade.

Bullish Signals
  • Bristol Myers Squibb is trading at a low valuation of 9.4x forward earnings compared to the 18.5x average for healthcare peers.
  • Second-quarter revenue grew 6% year-over-year to $13 billion while non-GAAP EPS surged 40% to $2.04.
  • The company successfully launched Opdivo Qvantig, a subcutaneous version of its cancer drug that may help retain patients as the original formulation loses patent exclusivity.
  • Bristol Myers has a robust pipeline including pumitamig and milvexian designed to replace revenue lost from upcoming patent cliffs on Eliquis and Opdivo.
  • The stock provides an attractive 4% forward dividend yield, more than triple the S&P 500 average of 1.1%, with a history of increasing payouts by 65.8% over the past decade.
Risk Factors
  • The market anticipates that generic and biosimilar competition for Eliquis and Opdivo could cause revenue and earnings growth to slow or reverse in the coming years.
Full Analysis
Bristol Myers Squibb (NYSE: BMY) is currently trading at approximately 9.4x forward earnings, significantly below the 18.5x average for healthcare stocks, presenting a potential value opportunity despite recent patent cliffs affecting its top-selling drugs like Revlimid. The company's financial performance in the second quarter showed resilience with revenue increasing 6% year-over-year to $13 billion and non-GAAP earnings per share jumping 40% to $2.04, driven largely by Eliquis and Opdivo which together accounted for over half of total revenue. To mitigate future risks from patent expirations on Eliquis and Opdivo, Bristol Myers is leveraging new formulations like the subcutaneous Opdivo Qvantig and growing its pipeline with candidates such as pumitamig and milvexian to replace declining sales. Beyond product innovation, the stock offers an attractive 4% forward dividend yield compared to the S&P 500 average of 1.1%, supported by a decade-long payout increase of 65.8%, making it a candidate for long-term income-focused investors.